Genmab A/S
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GNMSF research report →
About the company
Genmab A/S, founded in 1999 and based in Copenhagen, Denmark, is a biopharmaceutical firm focused on developing antibody-based therapeutics to treat cancer and a range of other diseases. The company markets several key products, including DARZALEX (daratumumab) for multiple myeloma, teprotumumab for thyroid eye disease, ofatumumab to address chronic lymphocytic leukemia (CLL) and multiple sclerosis, and Amivantamab for advanced or metastatic gastric, esophageal, and non-small cell lung cancers. Their extensive pipeline includes daratumumab, also being explored for non-MM blood cancers and AL amyloidosis, along with GEN1047, tisotumab vedotin for cervical, ovarian, and other solid cancers, and specialized DuoBody and HexaBody platforms targeting various solid tumors and hematological malignancies, such as Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and CLL.
- CEO
- Jan van de Winkel
- IPO
- 2010
- Employees
- 2,638
- HQ
- Copenhagen, DK
Price Chart
- Market Cap
- $16.88B
- P/E
- 21.49
- P/S
- 1.87
- P/B
- 3.09
- EV/EBITDA
- 15.16
- Div Yield
- 0.00%
- Gross Margin
- 38.65%
- Op Margin
- 13.67%
- Net Margin
- 8.73%
- ROE
- 14.53%
- ROIC
- 8.89%
- Revenue
- $3.85B · -82.11%
- Net Income
- $996.93M · -87.29%
- EPS
- $16.04 · -86.88%
- Op Income
- $1.29B
- FCF YoY
- -84.32%
- 52W High
- $352.00
- 52W Low
- $198.51
- 50D MA
- $259.07
- 200D MA
- $292.25
- Beta
- 0.69
- Avg Volume
- 1.92K
Get TickerSpark's AI analysis on GNMSF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our GNMSF coverage
Recent articles, reports, and earnings notes.
No research on GNMSF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GNMSF report →Similar companies
Peers in the same neighborhood.